newsfilter
← Latest News
GlobeNewswire·

Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026

  • Nkarta, Inc. will host a webcast on Monday, November 9, 2026, at 8:00 a.m. ET to review initial clinical data from its Ntrust program.
  • The presentation will cover NKX019 in myositis & systemic sclerosis at the American College of Rheumatology (ACR) Convergence 2026 in Orlando.
  • The Ntrust-1 (NCT06557265) & Ntrust-2 (NCT06733935) trials are multi-center, open-label, dose-escalation studies evaluating CD19-targeted CAR-NK cell therapy.
  • Leading indications for the trials include myositis, systemic sclerosis, ANCA-associated vasculitis, rheumatoid arthritis, lupus nephritis, & primary membranous nephropathy.
  • Patients receive up to 12 per dose level per disease indication, followed by lymphodepletion & a three-dose cycle of NKX019.
  • NKX019 is an allogeneic, off-the-shelf immunotherapy engineered with a humanized CD19-directed CAR & membrane-bound interleukin-15.
  • The therapy aims to eliminate pathogenic B cells to reset the immune system & achieve durable remission in autoimmune diseases.
Company
Nkarta, Inc.
Keywords
Nasdaq:NKTX, Nkarta, Inc.